Extended Data Fig. 2: Effect of targeting the Gαs/PKA signaling pathway in CD8 T cells.
From: The GPCR–Gαs–PKA signaling axis promotes T cell dysfunction and cancer immunotherapy failure
a, Upregulation of inhibitory receptors and decrease of IFNγ and TNF in chronically versus acutely simulated CD8 T cells. The average relative expression and s.e.m. are shown (n = 6 biologically independent samples). b, Significant decrease of IFNγ or TNF with Gαs agonists in chronically stimulated CD8 T cells. The average relative expression and s.e.m. are shown (n = 6 biologically independent samples). c, Significant decrease of Ki-67 and viability with Gαs agonists in chronically stimulated CD8 T cells. The average relative expression and s.e.m. are shown (n = 6 biologically independent samples). d, Representative flow cytometry plots showing expression of Tim-3 and PD-1 in chronically stimulated CD8 T cells after treatment with 1 µM PGE2 (P), 5 µM Dobutamine (D), or 5 µM CGS-21860 (C). e, Effect of CXCL10 on PGE2-mediated decrease in IFNγ and TNFα The average frequency and s.e.m. are shown (n = 3 per group). Statistical significance was determined by two-way ANOVA. Unless indicated otherwise, statistical significance was determined by two-tailed unpaired Student’s t-test.
